Melaninprobe-1, an 18F-picolinamide-based PET probe, is utilized for PET imaging of malignant melanoma. It demonstrates remarkable tumor targeting efficacy, superior tumor imaging contrasts, favorable biodistribution profiles, and robust in vivo stability.
Melanoma is a lethal skin cancer. The early detection of melanoma using positron emission tomography (PET) probes is critical for improving the survival of melanoma patients. Melaninprobe-2 is a non-radioactive bromo-picolinamide precursor that has been used for the synthesis of18F-picolinamides based PET probe (melaninprobe-1). The tumor-targeting efficacy and imaging property of three melaninprobes were evaluated in B16F10 tumor-bearing mice.18F-1 and18F-3 had much lower tumor uptake compared with18F-2 (Melaninprobe-2), which were 12.74 ± 1.70, 16.61 ± 2.60, and 16.87 ± 1.23 %ID g at 0.5, 1, and 2 h, respectively[1].